LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors

Luo, Guopei; Lei, Yu; Jin, Chen; Yang, Feng; Fu, Deliang; Jiang, Long; Xu, Jin; Zhan, Changyou; Lu, Weiyue

doi:10.1016/j.ijpharm.2009.10.014

Cited by 137 publications

(81 citation statements)

References 29 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[20] PEG-PCL diblock copolymers can produce NP of uniform size (around 50 nm) that can selectively pass through the gaps in lymphatic endothelium (30-100 nm). [43] Additionally, studies have shown that particles with a size above 20 nm accumulate into the lymphatics, however, when the particle size exceeds 100 nm the rate of particle drainage from the interstitum slows significantly.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

A three-drug nanoscale drug delivery system designed for preferential lymphatic uptake for the treatment of metastatic melanoma

Doddapaneni

Kyryachenko

Chagani

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

Metastatic Melanoma has a high mortality rate due to lymphatic progression of the disease. Current treatment is surgery followed by radiation and intravenous chemotherapy. However, drawbacks for current chemotherapeutics lie in the fact that they develop resistance and do not achieve therapeutic concentrations in the lymphatic system. We hypothesize that a three-drug nanoscale drug delivery system, tailored for lymphatic uptake, administered subcutaneously, will have decreased drug resistance and therefore offer better therapeutic outcomes. We prepared and characterized nanoparticles (NP) with docetaxel, everolimus, and LY294002 in polyethyleneglycol-block-poly(ε-caprolactone) (PEG-PCL) polymer with different charge distributions by modifying the ratio of anionic and neutral end groups on the PEG block. These NP are similarly sized (~ 48nm), with neutral, partially charged, or fully charged surface. The NP are able to load ~ 2mg/mL of each drug and are stable for 24 h. The NP are assessed for safety and efficacy in two transgenic metastatic melanoma mouse models. All the NP were safe in both models based on general appearance, weight changes, death, and blood biochemical analyses. The partially charged NP are most effective in decreasing the number of melanocytes at both the proximal (sentinel) lymph node (LN) and the distal LN from the injection site. The neutral NP are efficacious at the proximal LN, while the fully charged NP have no effect on either LN. Thus, our data indicates that the NP surface charge and lymphatic efficacy are closely tied to each other and the partially charged NP have the highest potential in treating metastatic melanoma. GRAPHICAL ABSTRACT

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

A three-drug nanoscale drug delivery system designed for preferential lymphatic uptake for the treatment of metastatic melanoma

Doddapaneni

Kyryachenko

Chagani

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…There are several polymers for preparing PNPs, such as poly-ε-caprolactone, 164 polyacrylamide, 165 polyacrylate, 166 DNA, 167 chitosan, [167][168][169] and gelatin. 170 After a polymerization reaction, drugs may be immobilized on the surface of the PNPs 171 or encapsulated in their structure during the polymerization processing. 172 The release of the drug may occur by desorption, diffusion, or erosion of PNPs in the target tissue.…”

Section: Polymeric Npsmentioning

confidence: 99%

Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Voltan¹,

Quindós²,

Alarcón³

et al. 2016

IJN

View full text Add to dashboard Cite

Invasive mycoses are a major problem for immunocompromised individuals and patients in intensive care units. Morbidity and mortality rates of these infections are high because of late diagnosis and delayed treatment. Moreover, the number of available antifungal agents is low, and there are problems with toxicity and resistance. Alternatives for treating invasive fungal infections are necessary. Nanostructured systems could be excellent carriers for antifungal drugs, reducing toxicity and targeting their action. The use of nanostructured systems for antifungal therapy began in the 1990s, with the appearance of lipid formulations of amphotericin B. This review encompasses different antifungal drug delivery systems, such as liposomes, carriers based on solid lipids and nanostructure lipids, polymeric nanoparticles, dendrimers, and others. All these delivery systems have advantages and disadvantages. Main advantages are the improvement in the antifungal properties, such as bioavailability, reduction in toxicity, and target tissue, which facilitates innovative therapeutic techniques. Conversely, a major disadvantage is the high cost of production. In the near future, the use of nanosystems for drug delivery strategies can be used for delivering peptides, including mucoadhesive systems for the treatment of oral and vaginal candidiasis.

show abstract

“…Luo et al synthesized an NP specific to tumor lymphatics conjugated with LyP-1 [70]. They used copolymers of maleimide-PEG-poly(lactic-co-glycolic) acid (PLGA) which were conjugated with fluorescein isothiocyanate (FTIC) labelled LyP-1.…”

Section: Lymphatic Systemmentioning

confidence: 99%

Theranostic Probes for Targeting Tumor Microenvironment: An Overview

Sikkandhar

Nedumaran

Ravichandar

et al. 2017

Preprint

View full text Add to dashboard Cite

Long gone was the time when tumors were thought to be insular masses of cells, residing independently at specific sites in an organ. Now, researchers gradually realize that tumors interact with the extracellular matrix (ECM), blood vessels, connective tissues and immune cells in their environment, which is now known as the tumor microenvironment (TME). It is found that the interactions between tumors and their surrounding promote tumor growth, invasion and metastasis. The dynamics and diversity of TME cause the tumors to be heterogeneous and thus pose a challenge for cancer diagnosis, drug design and therapy. As TME is significant in enhancing tumor progression, it is vital to identify the different components in the TME. This review explores how different factors in the TME supply tumors with the required growth factors and signaling molecules to proliferate, invade and metastasis. We also examine the development of TME-targeted nanotheranostics over the recent years for cancer therapy, diagnosis and anticancer drug delivery system. This review further discusses the limitations and future perspective of nanoparticle based theranostics when used in combination with current imaging modalities like Optical Imaging, Magnetic Resonance Imaging (MRI) and Nuclear Imaging (PET and SPECT).

show abstract

LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors

Cited by 137 publications

References 29 publications

A three-drug nanoscale drug delivery system designed for preferential lymphatic uptake for the treatment of metastatic melanoma

A three-drug nanoscale drug delivery system designed for preferential lymphatic uptake for the treatment of metastatic melanoma

Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Theranostic Probes for Targeting Tumor Microenvironment: An Overview

Contact Info

Product

Resources

About